Provided by Tiger Trade Technology Pte. Ltd.

Urogen Pharma Ltd.

43.67
-1.3300-2.96%
Volume:57.56K
Turnover:2.53M
Market Cap:2.13B
PE:-22.17
High:44.48
Open:44.25
Low:43.12
Close:45.00
52wk High:50.81
52wk Low:15.86
Shares:48.68M
Float Shares:43.35M
Volume Ratio:0.62
T/O Rate:0.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9700
EPS(LYR):-3.1901
ROE:-1481.26%
ROA:-18.06%
PB:-16.06
PE(LYR):-13.69

Loading ...

Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress

Dow Jones
·
Yesterday

UroGen Grants Inducement RSUs to 19 New Employees Covering up to 117,100 Shares

Reuters
·
Sep 04

UroGen Pharma CMO Mark Schoenberg Sells 60,677 Common Shares for $2.86 Million

Reuters
·
Aug 25

UroGen Pharma and IntraGel sign investment agreements in oncology therapies

TIPRANKS
·
Aug 20

UroGen Invests up to $7 Million in IntraGel Equity

Reuters
·
Aug 20

Press Release: UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

Dow Jones
·
Aug 20

UroGen Submits FDA NDA for UGN-103 Bladder Cancer Treatment

Reuters
·
Aug 17

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 12

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)

TIPRANKS
·
Aug 06

UroGen Pharma is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 06

Urogen Pharma Ltd : TD Cowen Raises Target Price to $60 from $50

THOMSON REUTERS
·
Aug 06

Exelixis Q2 Revenue Misses Analyst Estimates, Lowers 2026 Outlook

Reuters
·
Aug 06

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 06

Urogen Pharma Ltd Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

UroGen Pharma Q2 Revenue Beats on Strong Zusduri Sales

Reuters
·
Aug 05

Earnings Flash (URGN) UroGen Pharma Posts Q2 Net Loss $0.28 a Share, vs. FactSet Est of $0.27 Loss

MT Newswires Live
·
Aug 05

UroGen Pharma Q2 EPS $(0.28) Beats $(0.29) Estimate, Sales $72.456M Beat $63.526M Estimate

Benzinga Earnings
·
Aug 05

Urogen Pharma is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 21

Urogen Pharma Ltd : Guggenheim Raises Target Price to $42 from $32

THOMSON REUTERS
·
Jul 21

Urogen Pharma Ltd : TD Cowen Raises Target Price to $50 from $35

THOMSON REUTERS
·
Jul 20